Trading of Cue Biopharma was halted at 09:38 AM ET due to "LULD Pause" and resumed at 09:48 AM ET.

NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

Cue Biopharma logo
$4.55 -0.21 (-4.43%)
As of 09:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Cue Biopharma Stock (NASDAQ:CUE)

Advanced

Key Stats

Today's Range
$3.85
▼
$4.62
50-Day Range
$2.83
▼
$37.84
52-Week Range
$2.83
▼
$45.50
Volume
542,749 shs
Average Volume
406,816 shs
Market Capitalization
$33.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.00
Consensus Rating
Hold

Company Overview

Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders.

The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.

Based in Cambridge, Massachusetts, Cue Biopharma works in the biotechnology sector. Its approach focuses on engineering biologics to shape the body’s T-cell response rather than broadly activating or suppressing the immune system.

AI Generated. May Contain Errors.

Cue Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CUE MarketRank™: 
2.458230621745 of 5 stars

Cue Biopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 935th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cue Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cue Biopharma has a consensus price target of $83.00, representing about 1,643.7% upside from its current price of $4.76.

  • Amount of Analyst Coverage

    Cue Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cue Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Cue Biopharma are expected to grow in the coming year, from ($21.79) to ($8.70) per share.

  • Price to Book Value per Share Ratio

    Cue Biopharma has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.90% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 7.57.
  • Change versus previous month

    Short interest in Cue Biopharma has recently increased by 8.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cue Biopharma does not currently pay a dividend.

  • Dividend Growth

    Cue Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Cue Biopharma has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Cue Biopharma this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cue Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,260.00 in company stock.

  • Percentage Held by Insiders

    14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    35.04% of the stock of Cue Biopharma is held by institutions.

  • Read more about Cue Biopharma's insider trading history.
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CUE Stock News Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Cue Biopharma (CUE) Set to Release Earnings on Wednesday
See More Headlines

CUE Stock Analysis - Frequently Asked Questions

Cue Biopharma's stock was trading at $274.86 at the start of the year. Since then, CUE stock has decreased by 98.3% and is now trading at $4.76.

Cue Biopharma, Inc. (NASDAQ:CUE) released its earnings results on Monday, November, 16th. The company reported ($4.74) earnings per share for the quarter, missing analysts' consensus estimates of ($2.24) by $2.50. The company earned $132 thousand during the quarter, compared to analysts' expectations of $1.03 million. Cue Biopharma had a negative net margin of 579.95% and a negative trailing twelve-month return on equity of 820.77%.

Shares of Cue Biopharma reverse split on Thursday, April 23rd 2026.The 1-30 reverse split was announced on Wednesday, April 22nd 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 22nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Cue Biopharma (CUE) raised $62 million in an initial public offering (IPO) on Tuesday, January 2nd 2018. The company issued 8,820,710 shares at a price of $6.00-$8.00 per share.

Cue Biopharma's top institutional investors include Nantahala Capital Management LLC (1.32%), State Street Corp (0.44%), Texas Capital Bank Wealth Management Services Inc (0.38%) and Robertson Stephens Wealth Management LLC (0.15%). Insiders that own company stock include Shao-Lee Lin, Sumita Ray, Michael Vincent Meluzio and Daniel R Passeri.
View institutional ownership trends
.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Atomera (ATOM), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU).

Company Calendar

Last Earnings
11/16/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CUE
CIK
1645460
Fax
N/A
Employees
29
Year Founded
2015

Price Target and Rating

High Price Target
$83.00
Low Price Target
$83.00
Potential Upside/Downside
+1,773.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($29.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.60 million
Net Margins
-579.95%
Pretax Margin
-434.50%
Return on Equity
-820.77%
Return on Assets
-398.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.25
Quick Ratio
1.25

Sales & Book Value

Annual Sales
$27.47 million
Price / Sales
1.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.08 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
7,260,000
Free Float
6,206,000
Market Cap
$32.16 million
Optionable
No Data
Beta
2.79

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CUE) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners